top of page

- Jun 4, 2023

Making the case for allo durability at #ASCO23 with Allogene’s CEO

Allogene CEO David Chang describes the data his company presented at ASCO on Saturday and makes the case for the durability of the response.

Recent Posts

The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens

Merck KGaA's head of global R&D and CMO gives an overview of the company's programs and its appetite for business development

London's Epsilogen completed a £12.5 million Series B expansion this week to take its IgE based folate receptor alpha program into a phase 1b study

Comments

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

bottom of page